GLP Watchdog

altRX vs Ivy Rx

altRX has an open FDA warning letter dated June 8, 2026. Ivy Rx has none. On compounded tirzepatide injection, altRX costs $1,776 less a year at standing rates: $149 a month against $297 a month at Ivy Rx. It is one of two products the two sell at comparable terms.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / Ivy Rx

Featured pick (affiliate partner)

altRX logo

altRX

8.8/10

Ivy Rx logo

Ivy Rx

7.3/10

FDA warning letters
None on record
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
None named in our record
Lowest standing price
$89/moCompounded semaglutide injection
$197/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRX
Visit Ivy Rx

altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Ivy Rx pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Ivy Rx 7.3). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. Ivy Rx has none.

  2. 02

    altRX names four pharmacies. Ivy Rx names no compounding pharmacy in our record.

  3. 03

    On compounded tirzepatide injection, altRX costs $1,776 less a year at standing rates: $149 a month against $297 a month at Ivy Rx. It is one of two products the two sell at comparable terms.

  4. 04

    Only altRX lists a price for brand-name semaglutide pen and brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

Ivy Rx

Compounded semaglutide injection

$89/moLower

$1,068 a year

$197/mo

$2,364 a year

Compounded tirzepatide injection

$149/moLower

$1,788 a year

$297/mo

$3,564 a year

Brand-name semaglutide pen

$1,149/mo

$13,788 a year

Not sold or not priced
Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
None
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
All transactions are final; no returns
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. altRX: September 28, 2026. Ivy Rx: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
Featured pick (affiliate partner)
  • $1,296 a year less on compounded semaglutide injection
  • $1,776 a year less on compounded tirzepatide injection
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Ivy Rx does not price
  • Names its compounding pharmacy
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for Ivy Rx

7.3/10
  • No FDA warning letter on record
  • Names no compounding pharmacy
Visit Ivy Rx

Scores

altRX 8.8 · Ivy Rx 7.3 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs Ivy Rx: questions

altRX has an open FDA warning letter dated June 8, 2026. Ivy Rx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. Ivy Rx names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
altRX, by $1,296 a year at standing rates. altRX: $89 a month, about $1,068 a year. Ivy Rx: $197 a month, about $2,364 a year.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. Ivy Rx states you can cancel at any time; refunds: all transactions are final; no returns.
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Ivy Rx pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Ivy Rx 7.3).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks